Supplements could soothe red faces: new trial tests collagen and MSM
NCT ID NCT07345195
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether taking daily supplements containing collagen, MSM, and vitamin C for 16 weeks can reduce facial redness and spider veins in healthy women aged 35–65. Ninety participants with stable facial redness will be randomly assigned to one of two supplement doses or a placebo. The main goal is to see if the supplements improve redness compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- collagen, methylsulfonylmethane (MSM), and vitamin C dietary supplement
- What this could lead to
- If it works, this could point toward a simple supplement to help reduce facial redness and visible blood vessels.
- What could go wrong
- This is an early-stage, small trial (90 people) testing dietary supplements, not a drug. Results may show no benefit over placebo, and effects may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ERYTHEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
VIST - Faculty of Applied Sciences, Institute of Cosmetics
Ljubljana, 1000, Slovenia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Green tea compound EGCG put to the test for clearer, more hydrated skin
- Mushroom cream soothes baby skin rashes in new study
- Eye drops vs laser: cheap acne redness fix tested
- Immunotherapy shows promise in controlling advanced breast cancer after chemo
- Collagen pills may boost skin firmness and reduce wrinkles
- New hope for aggressive breast cancer: targeted combo before surgery